Collectively, these data provide a foundation for vigilance about future consideration of clinical development of DLL3-targeted immunotherapeutic agents for neuroblastoma and other potentially other DLL3-expressing neuroendocrine tumors. This evidence concerns the gene DLL3 and neuroblastoma.